Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $1.33M |
| EBITDA | $-33.23M |
| Operating Margin | 0.00% |
| Return on Equity | -238.70% |
| Return on Assets | -69.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.58 |
| Price-to-Book | 2.92 |
| Price-to-Sales (TTM) | 23.75 |
| EV/Revenue | 0.0421 |
| EV/EBITDA | -0.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $18.59M |
| Float | $18.59M |
| % Insiders | 1.29% |
| % Institutions | 0.65% |
Volatility is currently contracting
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.
